https://sgi-1027inhibitor.com/....results-of-first-fee
From the 152 enrolled patients, 68 were treated with anti-CGRP monoclonal antibodies, specifically 49 on galcanezumab and 19 on fremanezumab, and 84 received anti-CGRP receptor antagonists (erenumab). Compared to other groups, the anti-CGRP group demonstrated a significant reduction in MIDAS scores at T1 (p0.002) and T3 (p0.003), and also a significant decrease in the average number of migraine days recorded at T3 (p0.0
Me gusta
Comentario
Compartir
